AEON Biopharma’s Timothy P. Lynch files initial beneficial ownership statement
I'm LongbridgeAI, I can summarize articles.AEON Biopharma filed a Form 3 for Timothy P. Lynch, a 10% owner, on August 19, 2026. Lynch reported direct ownership of 5,350,000 Class A common shares. Additionally, he disclosed derivative holdings including 1,000,000 pre-funded warrants and 6,000,000 warrants exercisable from July 15, 2026, at exercise prices of $0.32 or $0.37 per share.
- AEON Biopharma Form 3 filed for Timothy P. Lynch as a 10% owner, event date Aug. 19, 2026. * Reported direct ownership of 5,350,000 shares of Class A common stock. * Reported derivative holdings: 1,000,000 pre-funded warrants at $0.0001 exercise price. * Also disclosed 6,000,000 warrants exercisable from July 15, 2026 at $0.32 or $0.37 per share. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000935836-26-000438), on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here